Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 10/20 | 0.68 |
| ▸ | BRAF | P15056 | 9/20 | 0.68 |
| ▸ | RAF1 | P04049 | 6/20 | 0.68 |
| ▸ | RET | P07949 | 4/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.68 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.68 |
| ▸ | ABL1 | P00519 | 2/20 | 0.68 |
| ▸ | HTR1A | P08908 | 2/20 | 0.68 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | KIT | P10721 | 2/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.68 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.68 |
| ▸ | FLT1 | P17948 | 2/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.68 |
| ▸ | EPHA1 | P21709 | 2/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.68 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.68 |
| ▸ | TTK | P33981 | 2/20 | 0.68 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15114776 | 1.00 | KDR (0.68) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL14714846 | 0.95 | KDR (0.62) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL29746649 | 0.91 | KDR (0.58) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL15114775 | 0.91 | KDR (0.58) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL29733289 | 0.91 | RAF1 (0.67) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL548256 | 0.91 | RAF1 (0.67) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL31323421 | 0.86 | RAF1 (0.54) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL14481108 | 0.86 | RAF1 (0.60) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL29523346 | 0.83 | KDR (0.59) | KDRBRAFRAF1RETRIPK2 | |
| SCHEMBL16851820 | 0.82 | BRAF (0.64) | KDRBRAFRAF1RETRIPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11951166-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-09 | — | — | US | claimed |
| US-11517622-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | BAYER HEALTHCARE LLC (US) | 2022-12-06 | — | — | US | claimed |
| US-20220133888-A1 | COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2022-05-05 | — | — | US | claimed |
| EP-3630112-B9 | COMBINATION OF REGORAFENIB AND NIVOLUMAB FOR TREATING CANCER | BAYER HEALTHCARE LLC (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117899212-A | Combination of regorafenib and a PD-1/PD-L1 (2) inhibitor for the treatment of cancer | 拜耳医药保健有限责任公司 | 2024-04-19 | — | — | CN | disclosed |
| US-11951166-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2024-04-09 | — | — | US | disclosed |
| EP-4342542-A2 | COMBINATION OF REGORAFENIB AND NIVOLUMAB FOR TREATING CANCER | Bayer HealthCare LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-3630112-B1 | COMBINATION OF REGORAFENIB AND NIVOLUMAB FOR TREATING CANCER | BAYER HEALTHCARE LLC (US) | 2024-01-31 | — | — | EP | disclosed |
| CN-116392484-A | Coated pharmaceutical composition containing regorafenib | 拜尔健康护理有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116392598-A | Coated pharmaceutical composition containing regorafenib | 拜尔健康护理有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
| CN-116392485-A | Coated pharmaceutical composition containing regorafenib | 拜尔健康护理有限责任公司 | 2023-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951166-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | PDCD1, CD274, PDCD1LG2 | KDR 1071/4885BRAF 9/4885RAF1 18/4885 |
| US-20220133888-A1 | COMBINATION OF REGORAFENIB AND PD-1/PD-L1(2) INHIBITORS FOR TREATING CANCER | PDCD1, CD274, PDCD1LG2 | KDR 1071/4885BRAF 9/4885RAF1 18/4885 |
| US-11517622-B2 | Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer | PDCD1, CD274, PDCD1LG2 | KDR 1071/4885BRAF 9/4885RAF1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.